Myovant Sciences Ltd (MYOV) is trading 36% higher at $24.405 today. Shares of the stock are strongly surpassing other names in the space on what is turning out to be a mildly cheery day for the Health Care sector. The market is undergoing a significant macro move (2.02%) which could be a factor in the stock's movement.
-Myovant Sciences has rejected a $2.5 billion takeover bid from Sumitovant
Myovant Sciences Ltd has been trading between a 52-week high of $24.95 and a 52-week low of $7.67. The stock has a market cap of $2.34 Billion.
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis.
As you can imagine, the internet had a few things to say about the price move. Here's a few choice comments from the Reddit Traderverse™: